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The (pro)renin receptor is a protein that binds prorenin and
renin in tissues, leading to their activation and, at the same
time, to the initiation of intracellular signaling. The activation
of local renin–angiotensin systems may play an important
role in tissue damage induced by cardiovascular diseases and
diabetes. However, (pro)renin receptor is also called ATP6ap2
because it has been shown to be associated with vacuolar
Hþ -ATPase involvement in vesicular acidification and
signaling in cells. Notably, lack of the protein in vertebrates
leads to developmental alterations and early embryonic
lethality probably as a result of the recently discovered role
of the (pro)renin receptor and the vacuolar Hþ -ATPase in
Wnt signaling. This review summarizes the current findings
about these two functions of (pro)renin receptor/ATP6ap2
pointing out the possible links between both.
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Until recently, the only function assigned to renin and its
precursor prorenin (after activation) was the cleavage of
angiotensinogen as a first step in the renin–angiotensin
system (RAS) finally resulting in several angiotensin peptides,
in particular angiotensin II (AngII), which acts via the AngII
receptors type 1 and 2 (AT1 and AT2). This activity is not
only observed in plasma but also locally in tissues forming
the basis for tissular RAS,1,2 which are of prime importance
for organ damage in cardiovascular diseases and diabetes.
However, since renin is hardly expressed outside the kidney
it remained unclear how the enzyme reaches these sites.
The discovery of the (pro)renin receptor ((P)RR/ATP6ap2)
has provided a possible solution for this problem.3 Renin
and prorenin (henceforth summarized as (pro)renin) bind
(P)RR/ATP6ap2 in organs where (pro)renin is normally not
generated leading to enzymatic activation and to intracellular
signaling (Figure 1).3–5 These data were ending the postulate
of prorenin as a precursor devoid of any activity and were
feeding the concept that (pro)renin can have angiotensin-
independent actions. These actions are of particular impor-
tance in light of the fact that (pro)renin levels in plasma and
tissues rise drastically after treatment with blockers of the
RAS such as AT1 antagonists, angiotensin-converting enzyme
(ACE) inhibitors and, in particular, renin inhibitors.6,7
However, (P)RR/ATP6ap2 had been discovered before as a
protein associated with the vacuolar Hþ -ATPase (V-ATPase)
in adrenal chromaffin cells8 and recent data mainly from
fish and frog models revealed essential functions in cellular
physiology and signaling, in particular Wnt signaling, which
are independent of the RAS9,10 (http://zfin.org). Consequently,
the question arose, which is the ‘real’ function of the protein,
(pro)renin binding or V-ATPase interaction, or are both
functions interconnected. This review will try to provide
a comprehensive description of the current knowledge
about (P)RR/ATP6ap2 and its interaction with (pro)renin
and V-ATPase, which, however, does not yet allow a final
answer to this question.
PRORENIN AND RENIN
Renin constitutes a crucial step within the RAS due to its
unique ability to proteolytically transform the precursor
angiotensinogen into angiotensin I (AngI), which is subse-
quently modified into various vasoactive peptides. Prorenin,
the inactive form of renin, does not show any enzymatic
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activity due to a 43-amino acid prosegment, which covers the
active site cleft. Prorenin can be activated in a proteolytic or a
non-proteolytic way. Proteolytic activation takes place mostly
in the juxtaglomerular apparatus and is characterized by the
removal of the prosegment. This process is irreversible and
involves ill-defined proconvertases. Non-proteolytic activa-
tion is a conformational change resulting in the unfolding
of the prosegment without any cleavage. Although this
reversible open conformation has only been achieved in vitro
by low pH or cold temperature, it suggested that
non-proteolytic activation is possible but not yet defined
in vivo.11,12
In physiological conditions, the plasma prorenin/renin
ratio is around 10/113 and chronic stimulation of the
juxtaglomerular apparatus decreases this ratio.14 This is
explained by the fact that prorenin is constitutively secreted
whereas renin is stored in secretory vesicles within the
juxtaglomerular apparatus in the kidney until release.
After bilateral nephrectomy, renin disappears and only
prorenin persists in blood.15 Thus, the kidney seems to be the
only renin-secreting organ and, more importantly, prorenin
is also secreted by other organs. Organs such as reproductive
tract, eye, adrenal and submandibular gland have been
described as extrarenal prorenin sources.16
Given the production of AngII at tissue level such as heart
and vascular wall in the absence of local renin expression,17 it
has been assumed that (pro)renin is recruited and locally
activated in these tissues by an unknown protein. Succes-
sively, three different receptors for (pro)renin were described.
First, an intracellular renin-binding protein emerged,18 but
its genetic deletion did not have any cardiovascular effects.19
Then, the mannose-6-phosphate/insulin-like growth factor II
receptor received particular attention. It binds and inter-
nalizes (pro)renin but contributes to its clearance and does
not result in AngI formation or intracellular signaling.20–24
Finally, (P)RR/ATP6ap2 was discovered and became the most
promising candidate.
(PRO)RENIN RECEPTOR
The full-length (pro)renin receptor ((P)RR/ATP6ap2) was
discovered in vitro in human mesangial cells and cloned
in 2002.3 The human ATP6AP2 gene located on the
X chromosome at locus p11.4, codes for a protein with
350-amino acids and a predicted mass of around 37 kDa and
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Figure 1 | Functions of (P)RR/ATP6ap2. For details see text. ACE, angiotensin-converting enzyme; AOG, angiotensinogen; ER, endoplasmic
reticulum; HRP, handle region peptide; MAPK, mitogen-activated protein kinase; PLZF, promyelocytic leukemia zinc finger.
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can be divided into four different domains: an N-terminal
signal peptide, an extracellular domain binding (pro)renin, a
single transmembrane domain and a short cytoplasmic
domain.25 Although prominently expressed in the brain,
(P)RR/ATP6ap2 has also been reported in various organs
such as the heart, liver, kidney, muscle, adrenal gland,
pancreas, ovary, and placenta (Figure 2).3 In addition, micro-
array data suggest an ubiquitous expression of its mRNA.26
In the kidney, (P)RR/ATP6ap2 expression has been detected
in mesangial cells,3 podocytes,27,28 and intercalated cells.29
Initially, (P)RR/ATP6ap2 was reported to bind equally
both renin and prorenin in vitro without internaliza-
tion.3,30,31 However, Batenburg et al.32 described differential
binding properties in vitro (KDa values of 7 and 20 nM for
prorenin and renin, respectively), arguing that prorenin may
be the main endogenous agonist in vivo. The binding of
prorenin to the receptor has two important consequences.
First, prorenin undergoes non-proteolytic activation, displays
full enzymatic activity and initiates AngII-dependent effects
(Figure 1).3,30,32 Unexpectedly, different studies using various
RAS inhibitors described that (P)RR/ATP6ap2 activation
triggers intracellular pathways in an AngII-independent
manner (Figure 1). Indeed, the mitogen-activated protein
kinase (MAPK) ERK1/2 is activated in cardiomyocytes,33
vascular smooth muscle cells,34 mesangial cells,4,35 and
monocytes.36 This results in the upregulation of pro-fibrotic
genes such as transforming growth factor b1,4,5,35,37 plasmino-
gen-activator inhibitor-1,4,5,31,35,38 fibronectin,5 collagen 1,5
and induction of proliferation in mesangial cells.4 In kidney
tissues, (P)RR/ATP6ap2 upregulates via ERK1/2 stimulation
inflammatory mediators such as cyclooxygenase-2 (COX2),37,39
interleukin-1 (IL-1b),39,40 and tumor necrosis factor a.40
Moreover, (P)RR/ATP6ap2 induces ERK1/2 activation in
endothelial cells and in the retinal pigment epithelium, where
it increases the expression of monocyte chemotactic protein,
vascular endothelial growth factor and again collagen 1.41–44
However, the physiological relevance of these ERK1/2 activa-
tion data has to be confirmed, since they have been obtained
with supraphysiological concentrations of (pro)renin and often
without loss-of-function controls for (P)RR/ATP6ap2, which
are necessary to support its direct interactions with (pro)renin.
Such controls were included, when the activation of
the promyelocytic leukemia zinc finger transcription factor
(PLZF) by (P)RR/ATP6ap2 (Figure 1) was first described in
cardiac tissue.45,46 PLZF downregulates (P)RR/ATP6ap2
expression in a negative feedback loop and, thereby, prevents
excessive receptor activation by high prorenin levels.45
However, this mechanism discovered in cell culture has also
to be taken with caution since Krebs et al.47 have described that
an increase in renal (pro)renin upregulates (P)RR/ATP6ap2
arguing for a positive feedback. However, Feldman et al.7 have
shown that extreme upregulation of plasma renin in renin-
inhibitor-treated rats even downregulates (P)RR/ATP6ap2
expression in the kidney.
The subcellular localization of (P)RR/ATP6ap2 is unusual
for a receptor. Only a minor amount of the protein was
found on the plasma membrane, the majority is located on
intracellular vesicles.33,45 In addition, a furin cleavage site on
the extracellular part of (P)RR/ATP6ap248 allows the release of
a 28kDa fragment during passage through the Golgi apparatus
(Figure 1), which could be detected in the supernatant of cells
expressing the protein.49 We have speculated that (pro)renin
might bind to this soluble form of (P)RR/ATP6ap2 and act
through an unknown receptor on cells (Figure 1).50 The cleavage
leaves behind a short protein consisting of the transmembrane
and the intracellular domains, which corresponds to the
M8-9 fragment of (P)RR/ATP6ap2 found to be associated
with V-ATPase8 (see (P)RR/ATP6ap2 and V-ATPase).
PRORENIN, (P)RR/ATP6ap2 AND PATHOLOGY
Prorenin
Although the RAS has a prominent role in the pathogenesis
of organ damage induced by diabetes and hypertension, there
is to date no clinical data ascertaining the relevance of
prorenin and (P)RR/ATP6ap2 in RAS-associated pathologies.
The question of a potential role of prorenin in pathology was
raised for the first time by the description that human
diabetic patients display 3 to 7-fold higher prorenin/renin
ratios in the blood.51–53 Experimental evidence was provided
by Ve´niant et al., who reported that transgenic rats with a
targeted prorenin expression in the liver and bearing high
plasma prorenin levels, develop glomerulosclerosis, cardiac
hypertrophy, and vascular damage at the age of 20 weeks,
independently of any hypertension.54 That such a phenotype
is due to a local activation of prorenin within tissues was
supported by the report that prorenin overexpression in mice
results in elevated AngI contents in the heart, without any
activation of the circulating RAS.55 Interestingly, the expres-
sion of a non-cleavable prorenin still resulted in AngI
production within tissues, indicating that proteolytic con-
version into renin is not a prerequisite for local actions of
prorenin.56 Taken together, these data support non-proteo-
lytic activation of prorenin possibly by (P)RR/ATP6ap2 as
a contributing factor for tissue damage.
However, several contradicting data urge us to reconsider
these findings. High prorenin levels are also found during
pregnancy in the maternal plasma (where they can rise by
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Figure 2 | Expression of (P)RR/ATP6ap2 in different rat organs.
Expression of (P)RR/ATP6ap2 was assessed in different organs
of male and female Sprague–Dawley rats by RNase protection
assay using each 20 mg total RNA with specific probes for rat
(P)RR/ATP6ap2 and b-actin.
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a factor of 10)57–59 in the absence of any obvious tissue
damage. Moreover, Campbell et al.60 re-evaluated the
phenotype of the same transgenic line of rats overexpressing
prorenin described by Ve´niant et al.54 On the contrary to the
first report, Campbell et al.60 observed only modest renal
lesions and myocardial fibrosis after 6 months of age. In
addition, these animals developed hypertension at 3 to 12
months of age, which likely caused the slight renal and
myocardial phenotypes. These results undermined prorenin
as a risk factor for tissue damage. Although the authors were
not able to explain the obvious discrepancy, this revised
phenotype was in accordance with other recent reports
published by different groups. Peters et al.61 reported that the
200-fold increased plasma prorenin levels in a rat model
bearing an inducible renin transgene was not sufficient to
induce glomerulosclerosis or cardiac fibrosis, despite a
moderate myocardial hypertrophy and a slight increase in
markers for hypertrophy, fibrosis, and oxidative stress in the
heart.62 Moreover, Mercure et al.63 reported that prorenin
overexpression in transgenic mice yielded only mild hyper-
tension, myocardial hypertrophy, and albuminuria without
cardiac fibrosis or renal injury. They even discussed beneficial
actions of prorenin, because in one line of their transgenic
mice tissue damage is lower than expected from the level of
blood pressure. High (pro)renin levels are also the con-
sequence of any pharmacological intervention in the RAS
including the use of ACE or renin inhibitors or AT1
antagonists.6,7 However, no cardiovascular damage has ever
been described to be induced by these treatments. In the
opposite, these drugs are among the most efficient for a
multitude of cardiovascular and metabolic diseases to avoid
tissue damage. In conclusion, the importance of (pro)renin
in organ damage remains controversial. It may not be
sufficient to elicit tissue damage per se, but require a specific
pathological environment to do so.
(P)RR/ATP6ap2
What about (P)RR/ATP6ap2? Several reports have described
a modulation of (P)RR/ATP6ap2 expression under patho-
logical conditions in vitro and in vivo, suggestive of its
involvement in tissue damage. Notably, (P)RR/ATP6ap2
expression has been shown to be upregulated in the kidney
of streptozotocin-induced diabetic rats,40,64 as well as in
mesangial cells upon a 14-day incubation with high glucose
concentrations in vitro.39 In addition, increased (P)RR/
ATP6ap2 expression has been reported in the remnant
kidney of nephrectomized rats,65,66 in the heart and kidney of
rats with congestive heart failure,67 in the heart of
spontaneously hypertensive rats,68 and in atherosclerotic
tissues.69 However, clinical and experimental reports depict-
ing its real impact in pathology are scarce. Recently, a
Japanese cohort study has revealed a significant association
between a polymorphism in the (P)RR/ATP6ap2 gene and
blood pressure in humans.70 This observation concurs with
reports from our group and others showing that the
overexpression of human (P)RR/ATP6ap2 in the rat leads
to cardiovascular alterations. We observed that a targeted
(P)RR/ATP6ap2 overexpression in the vasculature leads to
chronic hypertension after 6 months of age,48 and Kaneshiro
et al.71 reported that a ubiquitous overexpression leads to
glomerulosclerosis in an AngII-independent manner. How-
ever, these symptoms were mild and their onset was late in
life despite an early and drastic overexpression of the
transgene in both models not quite supporting an important
role of (P)RR/ATP6ap2 in local prorenin activation and
cardiovascular pathology.
However, the most interesting clinical observation came
from the description by Ramser et al.72 that a mutation in the
(P)RR/ATP6ap2 gene (leading to a reduction of 50% of the
functional protein) does not result in a cardiovascular
phenotype but leads to mental retardation. This is to date
the only report of a (P)RR/ATP6ap2 deficiency in mammals,
and it suggests important functions in brain development
and/or neurophysiology (see (P)RR/ATP6ap2 and V-ATPase).
Nevertheless, the lack of a gene-deficient mouse model
makes it difficult to assess in a specific manner the relevance
of (P)RR/ATP6ap2 in pathology. In addition, the lack of
information on (P)RR/ATP6ap2 structure (X-ray crystal-
lography has not been performed yet) hampers the develop-
ment of specific antagonists. To study the effects of (P)RR/
ATP6ap2 in pathology, Ichihara et al.73 have employed a
peptide of 10 amino acids named Handle Region decoy
Peptide (HRP) as a blocker of the prorenin/(P)RR/ATP6ap2
interaction.
(P)RR/ATP6ap2 INHIBITION AS THERAPEUTIC CONCEPT
HRP was designed on the basis of the prorenin ‘handle
region’ sequence described by Suzuki et al.12 as a decoy for
prorenin (but not renin) interacting with (P)RR/ATP6ap2
(Figure 1). In a series of seminal experiments, they described
the beneficial effects of this peptide on kidney damage
associated with experimental diabetes. In streptozotocin-
induced diabetic rats, a long-term treatment with HRP was
able to prevent the development of proteinuria and
glomerulosclerosis, independent of glycemia and could
reverse already established diabetic nephropathy.73,74 Ichihara
et al.75 also used diabetic mice deficient for the AT1a receptor
and treated with an ACE inhibitor. Although insensitive to
AngII, these mice still developed glomerulosclerosis, which
was consistent with observations that RAS blockers are
unable to completely prevent end stage organ damage
associated with diabetes.76–78 HRP could efficiently block
glomerulosclerosis in this model. These data were consistent
with a critical role of the (pro)renin/(P)RR/ATP6ap2
interaction in diabetic nephropathy.
Matavelli et al.40 recently confirmed the beneficial effects
of HRP in diabetic nephropathy. In addition to a reduced
albuminuria, they observed a significant reduction in the
amounts of pro-inflammatory cytokines such as tumor
necrosis factor a and IL-1b in the kidney, drawing the
conclusion that the (pro)renin/(P)RR/ATP6ap2 axis promotes
diabetic nephropathy by enhancing renal inflammation.
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Interestingly, they could not confirm the data of Ichihara
et al.73 showing that HRP treatment in diabetic rats normal-
ized AngII levels in the kidney.
The efficiency of HRP was further shown in other
pathologies including cardiac fibrosis in a genetic model of
hypertension (spontaneously hypertensive rats)68 as well as
ischemia-induced retinal neovascularization and ocular
inflammation in endotoxin-induced uveitis.79,80
However, several studies evaluating the efficiency of the
HRP in vitro and in vivo have failed to reproduce such
impressive results. Susic et al.81 could only confirm a mild
beneficial effect of HRP on cardiac hypertrophy in sponta-
neously hypertensive rats. HRP was inefficient in blocking the
development of albuminuria and cardiac hypertrophy in
transgenic mice with high circulating prorenin levels,
although used at concentrations 10 times higher than those
used by Ichihara et al.73 Krebs et al.82 could not prevent renal
damage by HRP in the Goldblatt hypertension model. Feldt
et al.36 could not show that HRP was blocking (pro)renin
binding to (P)RR/ATP6ap2 in monocytes in vitro, nor
could it block ERK1/2 signaling induced by (pro)renin
in monocytes and vascular smooth muscle cells in vitro.83
More interestingly, they could not block mortality and
nephrosclerosis with HRP in hypertension models such as
double-transgenic rats overexpressing human renin and
angiotensinogen83 and Goldblatt rats,84 whereas the renin
inhibitor aliskiren could. It can be argued that such
hypertensive models not only display high prorenin levels
but also high renin and high plasma AngII levels and
therefore are not suited to study the actions of HRP, which
has been designed to target prorenin only. However, these
data suggest that the efficiency of HRP as a therapeutic
compound for renovascular damage needs further examina-
tion, and raises the question whether this efficiency may be
pathology-dependent, with a better outcome in diabetes.
Moreover, although the capacity of HRP to competitively
block the binding of (pro)renin to (P)RR/ATP6ap2 has been
described in vitro,12,85 it cannot be excluded that this peptide
may have other targets in vivo. In particular, it is most likely
processed into smaller peptide metabolites in the circulation
with unpredictable and possibly beneficial effects on other
cardiovascular and inflammatory mediators. Confirming the
real specificity of HRP in vivo is a crucial point to ascertain
the roles described for (P)RR/ATP6ap2 in pathology.
(P)RR/ATP6ap2 AND V-ATPase
(P)RR/ATP6ap2 as V-ATPase subunit
Despite the efforts to understand the role of the (P)RR/
ATP6ap2 related to the RAS, we have to keep in mind that
(P)RR/ATP6ap2 was initially discovered not as a (pro)renin-
binding protein. In 1998, Ludwig et al. described a truncated
form (M8-9) of (P)RR/ATP6ap2 composed of the C-terminal
part and the transmembrane domain, which co-purified on
native polyacrylamide gels with the V-ATPase in chromaffin
cells of the adrenal medulla and was later named ATP6ap2 for
vacuolar Hþ -ATPase-associated protein 2.8 They erroneously
assigned an in-frame ATG immediately upstream of the short
fragment on the chromosome as start codon for the protein
not considering the possibility of proteolytic cleavage. When
full-length (P)RR/ATP6ap2 was discovered in 2002 by
Nguyen et al.3 the identity of the two proteins was not
immediately obvious leading to two different names for the
same protein.
(P)RR/ATP6ap2 is not only found in vertebrates but also
in the worm Caenorhabditis elegans and the insect Drosophila,
which do not possess any RAS. Interestingly, vertebrates and
invertebrates share a conserved sequence in the transmem-
brane and cytosolic domains corresponding to the V-ATPase-
associated M8-9 fragment, whereas the sequence coding for
the extracellular domain ((pro)renin-binding domain) is
conserved only in vertebrates.48,50 Based on these findings it
was postulated that (P)RR/ATP6ap2 has emerged from the
fusion of two genes in vertebrates: one gene encoding the
N-terminal part, which binds (pro)renin and another
one coding for the V-ATPase-associated part with an essential
role in cell survival.86 Alternatively, the N-terminal part of a
V-ATPase-associated protein may have acquired (pro)renin-
binding properties during evolution.50 As already stated
above, both parts of the protein are linked by a furin cleavage
site, which may allow their separation and functional
independence.
Localizations and functions of V-ATPase
The V-ATPase is a multiprotein complex composed of a
peripheral V1 domain (eight subunits) responsible for ATP
hydrolysis, a V0 domain (six subunits) responsible for proton
translocation and two accessory subunits (Ac45 and (P)RR/
ATP6ap2).8,87 The complexity is even higher given that some
subunits have different isoforms, the expression of which is
tissue-specific and may be involved in the intracellular
localization of the pump. V-ATPases are mainly within
intracellular membranes and regulate the pH of intracellular
compartments such as endosomes, lysosomes, synaptic
vesicles, and melanosomes among others.87,88 The resulting
acidic environment is crucial for different biological processes
including uncoupling of internalized ligand-receptor com-
plexes, recycling of receptors, processing and degradation of
proteins through pH-dependent enzymes, intracellular traf-
ficking and coupled transport of small molecules.89 In
addition, V-ATPases are present on the plasma membrane
of specific cell types where they have a role, for example, in
urinary acidification and bone resorption.90 The localization
of (P)RR/ATP6ap2 mainly in intracellular membranes and only
a minor part at the plasma membrane33,45 concurs with this
distribution of V-ATPase. Moreover, sequence analysis predicted
motifs in the cytosolic domain of (P)RR/ATP6ap2 targeting the
protein to distinct intracellular vesicle compartments.48
Experimental and clinical studies have emphasized the
critical roles of V-ATPases in physiology and pathophysio-
logy. Table 1 summarizes genetic defects for V-ATPase
subunits and the large range of their associated phenotypes
in different animal models and humans. In the mouse, gene
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Table 1 | Summary of genetic alterations in V-ATPase subunits and their associated phenotypes
Subunit Alteration Organism/cell line Phenotype Reference
V1 peripheral domain
A morpho. Zebrafish Impaired acid secretion and ion balance 117
A mut. Neurospora Progeny not viable 118
A mut. Yeast Mislocalization of vacuolar proteins 119
B mut. Yeast Mislocalization of vacuolar proteins 119
B KO Yeast Conditional lethality 120
B KO Drosophila Lethal phenotype at larval stage 121
B1 mut. Human Distal renal tubular acidosis with hearing loss 122,123
B1 mut. Human Distal renal tubular acidosis with preserved hearing 124
B1 KO Mouse Severe metabolic acidosis after oral acid loading 125
B1 mut. Rat IMCD cells Impaired proton pump assembly and trafficking 126
C dsRNA Caenorhabditis elegans Impaired ovulation and embryogenesis 127
C1 siRNA Mouse BMMs Defective F-actin ring formation and osteoclast
acidification activity
128
E mut. Yeast Impaired V-ATPase function 129
E1 mut. Zebrafish Oculocutaneous albinism, small head and eyes,
CNS necrosis, and embryonic lethality
10,97
F mut. Zebrafish Oculocutaneous albinism, small head and eyes,
CNS necrosis, and embryonic lethality
10,97
H mut. Zebrafish Oculocutaneous albinism, small head and eyes,
CNS necrosis, and embryonic lethality
10,97
V0 membrane-embedded domain
a mut. C. elegans Blockade of apical secretion of exosomes 130
a1 morpho. Zebrafish Impaired formation of phagolysosomes and
clearance of apoptotic neurons
131
a1 mut. Drosophila neurons Blockade in synaptic vesicle fusion with the
presynaptic membrane
132
a2 mut. Human Defective protein glycosylation and cutis laxa 133
a3 KO Mouse pancreatic b-cells Defective insulin secretion 134
a3 KO Mouse Severe osteopetrosis due to loss of extracellular
acidification
135
a3 mut. Human Deficient bone resorption and osteopetrosis 136–138
a3 mut. Mouse Deficient bone resorption and osteopetrosis 139
a3 siRNA Rat osteoclasts Decreased acidification and osteoclast inactivation 140
a4 mut. Human Distal renal tubular acidosis with hearing loss 123
c siRNA Rat BMMs Decreased osteoclast differentiation and bone
resorption in vitro
141
c KO Mouse Disruption of the Golgi apparatus and embryonic
mortality
142,143
c siRNA Human carcinoma in mice Decreased tumor invasion and metastasis 144
c mut. Zebrafish oculocutaneous albinism, retinal defects,
and embryonic lethality
10,97
c mut. Yeast Mislocalization of vacuolar proteins 119
c KO Yeast Conditional lethality 120
c dsRNA C. elegans Impaired ovulation and embryogenesis 127
c’’ dsRNA C. elegans Impaired ovulation and embryogenesis 127
d KO Mouse Embryonic mortality 145
d1 mut. Zebrafish Oculocutaneous albinism, small head and eyes,
CNS necrosis, and embryonic lethality
10,97
d2 KO Mouse Impaired osteoclast fusion and increased bone
formation
146
d2 shRNA Mouse BMMs Impaired osteoclast differentiation and extracellular
acidification
147
Accessory subunits
Ac45 mut. Zebrafish Oculocutaneous albinism, small head and eyes,
CNS necrosis and embryonic lethality
10,97
Ac45 KO Mouse Embryonic mortality 103
Ac45 mut. Mouse BMMs and RAW264.7 cells Altered association with V0 complex and decreased
bone resorption
148
ATP6ap2 mut. Zebrafish Oculocutaneous albinism, small head and eyes,
CNS necrosis and embryonic lethality
10
ATP6ap2 mut. Xenopus Defects in melanocytes and eye pigmentation,
small head, shortened tail
9
ATP6ap2 mut. Human X-linked mental retardation and epilepsy 72
Abbreviations: BMMs, bone marrow-derived monocytes; CNS, central nervous system; dsRNA, double-stranded RNA; IMCD, inner medullary collecting duct; KO, knockout;
morpho., morpholino antisense oligonucleotide injection; mut., mutation; shRNA, small hairpin RNA; siRNA, small interfering RNA.
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deletions of subunit c, d and the accessory protein Ac45 are
lethal. In contrast, mutations in other subunits lead to
various defects such as renal acidosis, cutis laxa (loose skin)
and osteopetrosis suggesting that some subunits have
different roles and localizations. Indeed, during osteoclast
differentiation, V-ATPases are relocated to the membrane
and permit an efficient extracellular acidification for bone
resorption.91 Like other V-ATPase subunits, the (P)RR/
ATP6ap2/ATP6ap2 has been described to be upregulated
during this differentiation in vitro but its role in osteoclast
function is yet unknown.92 V-ATPases and endosomal
acidification are also involved in the entry process of viruses
into cells93 and (P)RR/ATP6ap2, among other V-ATPase
subunits, has recently been discovered to be pivotal for
influenza virus infection.94,95
Interestingly, the only yet described human (P)RR/
ATP6ap2 mutation results in the deletion of exon 4 [D4-
(P)RR/ATP6ap2] and is associated with X-linked mental
retardation (XLMR) and epilepsy.72 This may be explained by
a defect in the function of synaptic vesicles due to
dysfunctional acidification because only one copy of the V-
ATPase, including (P)RR/ATP6ap2, is present per vesicle.88
Thus, the full functionality of this single V-ATPase molecule
is critical to supply the driving force for vesicle trafficking,
neurotransmitter uptake, and exocytosis and the lack of
(P)RR/ATP6ap2 may impair neurotransmission. Moreover,
the intracellular signaling triggered by (P)RR/ATP6ap2 after
(pro)renin binding may be important for disease etiology
because immortalized lymphocytes of one patient with
XLMR did not show any ERK1/2 activation in the presence
of renin.72 Furthermore, Contrepas et al.96 showed that the
D4-(P)RR mutant affects the trafficking of this receptor to
the neurite tips in vitro. However, further studies are
warranted to clarify the pathogenesis of the (P)RR/
ATP6ap2-dependent form of XLMR.
(P)RR/ATP6ap2 AND V-ATPase IN EMBRYONIC
DEVELOPMENT
Actually, the most relevant data for a crucial role of (P)RR/
ATP6ap2 as a V-ATPase accessory subunit have emerged from
studies with lower vertebrates such as zebrafish and Xenopus
frogs. Indeed, zebrafish with insertional mutations in genes
coding for V-ATPase subunits and (P)RR/ATP6ap2 share a
common embryonic phenotype10,97 (http://zfin.org). At day
2 of development, all mutants including the ones for (P)RR/
ATP6ap2 displayed abnormal body and eye pigmentation. At
day 5, all V-ATPase mutants developed multiple organ defects
(head, liver, gut, heart) and necrosis in the central nervous
system finally resulting in embryonic lethality. Accordingly,
when we knocked down (P)RR/ATP6ap2 in zebrafish
embryos using morpholino antisense oligonucleotide injec-
tions we also obtained abnormal pigmentation in the eyes,
head, and trunk and early lethality (G Sihn, unpublished
data). The pigmentation phenotypes may reflect a defect in
melanosome acidification and maturation because V-ATPase
is essential in the first steps of this process.98 The defects in
the nervous system may result from dysfunctional synaptic
vesicles as already discussed above for the XLMR due to the
(P)RR/ATP6ap2 mutation.
However, very recent data from Xenopus embryos and
cultured cells provide another intriguing explanation for
these phenotypes. Cruciat et al.9 characterized V-ATPase and
(P)RR/ATP6ap2 as essential components of Wnt signaling,
which is crucial for several processes in embryonic develop-
ment including neural patterning99,100 and melanocyte
differentiation.101 They show that phosphorylation of the
Wnt coreceptor LRP6, and thereby activation of intracellular
Wnt signaling, is depending on its sequestration in vesicles,
which are acidified by V-ATPase action (Figure 1). The
authors provided evidence that the pivotal link between LRP6
and V-ATPase is formed by (P)RR/ATP6ap2 (Figure 1). This
process is independent of (pro)renin9 and, therefore,
inhibitors of its interaction with (P)RR/ATP6ap2 (such as
HRP) should not interfere with Wnt-signaling. If however in
future, novel drugs become available, which inhibit (P)RR/
ATP6ap2 action, their influence on Wnt signaling need to be
critically assessed to avoid serious side effects.
In accordance with the lethal phenotype observed in
(P)RR/ATP6ap2-deficient zebrafish and Xenopus frogs, our
multiple attempts to generate (P)RR/ATP6ap2 knockout
mice also failed and only one low-level chimeric animal was
obtained without germ line transmission of the mutation
(Figure 3). Interestingly, for the V-ATPase accessory subunit
Ac45, which has also been shown to co-purify with the
Injected
blastocysts
473 16/31 30 1 0
Pregnant
fosters Pups Chimeras
Knockout
mice
Figure 3 |Attempts to generate (P)RR/ATP6ap2-knockout
mice. (a) Number of pregnant mice, pups, and chimeras obtained
after blastocyst injection of (P)RR/ATP6ap2-knockout ES cells
(RST307 from BayGenomics, http://baygenomics.ucsf.edu) and
re-implantation into foster mothers (C57Bl/6); no knockout mouse
was obtained subsequent to the breeding of the only chimera.
(b) Aspect of the only chimera, displaying very low chimerism
in the fur (arrowhead). (c) As comparison, a control chimera
obtained with non-modified ES cells with similar procedures
displaying 70–80% chimerism and germ line transmission.
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V-ATPase in bovine adrenal chromaffin granules,8,102 the
generation of knockout animals led to the same result: only
one low-chimeric mouse.103 Both accessory proteins are
encoded by the X-chromosome and, thus, embryonic stem
(ES) cells (which are male) with a targeted mutation lack the
respective proteins completely. Such cells can obviously not
participate in the development of a full organism and even a
minor contribution of them leads to the death of chimeras.
These findings are also in line with knockout studies on other
V-ATPase subunits (Table 1) that point to an essential role for
the V-ATPase during embryonic development, which may
involve Wnt signaling according to the data of Cruciat et al.9
Furthermore, b-catenin-knockout ES cells, which completely
lack canonical Wnt signaling, also do not allow embryonic
development when injected into host blastocysts.104
(P)RR/ATP6ap2, V-ATPase and Wnt signaling in kidney
How do V-ATPase functions relate to (P)RR/ATP6ap2 in the
kidney? The first evidence of a functional link between the
(P)RR/ATP6ap2 and the V-ATPase in this organ has recently
been provided by Advani et al.29 First, combining in situ
hybridization, immunohistochemistry and electron micro-
scopy, they have mapped the expression of the (P)RR/
ATP6ap2 in the distal nephron and collecting ducts. There,
(P)RR/ATP6ap2 was predominantly expressed in microvilli at
the apical surface of A-type intercalated cells where it co-
localized with the V-ATPase. In addition, in cultured
collecting duct cells, they described that not only (P)RR/
ATP6ap2 downregulation by siRNA but also bafilomycin, a
selective V-ATPase inhibitor attenuated the increase in ERK1/
2 phosphorylation induced by either renin or prorenin. These
results show that in the presence of AT1 and AT2 antagonists
(that is, AngII-independent), (pro)renin binds (P)RR/ATP6ap2
and activates V-ATPases followed by ERK1/2 activation.
Many questions are raised by this study. Given that the
antibody they used targets the C terminus of the (P)RR/
ATP6ap2, it is not clear whether the main form at the
membrane is the full protein or the furin-cleaved M8-9
fragment initially described by Ludwig et al.8 Moreover,
(P)RR/ATP6ap2 is located on the luminal membrane of the
intercalated cells and, thus, can only interact with (pro)renin
in the urine. Indeed, prorenin and renin have been found in
the urine of animals and humans,105,106 but it is not clear
whether under physiological conditions the urinary concen-
trations reach sufficient levels to initiate (P)RR/ATP6ap2
signaling. (Pro)renin is, however, also produced in neighboring
principal cells and may induce a paracrine interaction.107,108
Wnt signaling is a fundamental molecular pathway in
kidney organogenesis and physiology associated with numer-
ous kidney diseases such as cancer, fibrosis, cystic disease,
renal failure, and diabetic nephropathy.109,110 Recent studies
showed that aberrant activation of the Wnt-signaling path-
way promotes renal fibrosis, glomerulosclerosis, and protei-
nuria.111,112 In contrast, inhibition of this pathway was also
associated with kidney dysfunction and cystic ciliopa-
thy.113,114 It is predictable that (P)RR/ATP6ap2, based on
its pivotal function in Wnt signaling,9 is also implicated
in such processes. Further studies with cell-type specific
knockout mouse models are warranted to clarify this issue.
CONCLUSIONS
Can one formulate a unifying hypothesis about the inter-
connection between (pro)renin, (P)RR/ATP6ap2, V-ATPase
and Wnt signaling? Possibly, (P)RR/ATP6ap2 is a molecule
whose main function is the correct targeting and/or
functional assistance of V-ATPase in specific vesicles and
membrane compartments such as synaptic vesicles, melano-
somes or the specialized plasma membranes of osteoclasts
and A-intercalated cells. It may also be important for the
formation and/or function of so called ‘signaling endo-
somes’.115 In these compartments, receptor/ligand complexes
are sequestered, acidified, and acquire new competences. In
the Wnt pathway, their acidic environment is essential for
LRP6 phosphorylation and intracellular signal transduction
to activate b-catenin.9 G-protein-coupled receptors, for
example, AT1, need to be sequestered into such endosomes
to interact with b-arrestins and to initiate mitogenic signaling
including ERK1/2 phosphorylation (Figure 1).116 It is
unknown whether acidification of the vesicle by V-ATPase
is also required for this process. These functions of (P)RR/
ATP6ap2 and V-ATPase are most likely independent of
(pro)renin.9 Nevertheless, (pro)renin may bind to (P)RR/
ATP6ap2 in signaling endosomes, which could explain its
non-proteolytic activation (in the acid environment) and also
the observed slow-onset ERK1/2 phosphorylation, if one
assumes that the (pro)renin/(P)RR/ATP6ap2 complex can
somehow activate the b-arrestin-MAPK pathway (Figure 1).
At this time, a lot of this hypothesis is pure speculation and
needs to be verified by experimental approaches. Besides
cultured cells and lower vertebrate models, cell-type specific
(P)RR/ATP6ap2 knockout mice will be instrumental to this
purpose.
DISCLOSURE
All the authors declared no competing interests.
REFERENCES
1. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin
systems. Physiol Rev 2006; 86: 747–803.
2. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for
pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50:
439–465.
3. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin
receptor in angiotensin II production and cellular responses to renin.
J Clin Invest 2002; 109: 1417–1427.
4. Huang Y, Noble NA, Zhang J et al. Renin-stimulated TGF-beta1
expression is regulated by a mitogen-activated protein kinase in
mesangial cells. Kidney Int 2007; 72: 45–52.
5. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial
cell transforming growth factor-beta1 and matrix proteins through
receptor-mediated, angiotensin II-independent mechanisms. Kidney Int
2006; 69: 105–113.
6. Bader M, Ganten D. Regulation of renin: new evidence from cultured
cells and genetically modified mice. J Mol Med 2000; 78: 130–139.
7. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood
pressure, albuminuria, and (pro)renin receptor expression in diabetic
TG(mRen-2)27 rats. Hypertension 2008; 52: 130–136.
Kidney International (2010) 78, 246–256 253
G Sihn et al.: Update on the (pro)renin receptor r ev iew
8. Ludwig J, Kerscher S, Brandt U et al. Identification and characterization
of a novel 9.2-kDa membrane sector-associated protein of vacuolar
proton-ATPase from chromaffin granules. J Biol Chem 1998; 273:
10939–10947.
9. Cruciat CM, Ohkawara B, Acebron SP et al. Requirement of prorenin
receptor and vacuolar H+-ATPase-mediated acidification for Wnt
signaling. Science 2010; 327: 459–463.
10. Amsterdam A, Nissen RM, Sun Z et al. Identification of 315 genes
essential for early zebrafish development. Proc Natl Acad Sci USA 2004;
101: 12792–12797.
11. Pitarresi TM, Rubattu S, Heinrikson R et al. Reversible cryoactivation of
recombinant human prorenin. J Biol Chem 1992; 267: 11753–11759.
12. Suzuki F, Hayakawa M, Nakagawa T et al. Human prorenin has ‘gate and
handle’ regions for its non-proteolytic activation. J Biol Chem 2003; 278:
22217–22222.
13. Danser AH, Derkx FH, Schalekamp MA et al. Determinants of
interindividual variation of renin and prorenin concentrations: evidence
for a sexual dimorphism of (pro)renin levels in humans. J Hypertens
1998; 16: 853–862.
14. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin
receptor. Hypertension 2005; 46: 1069–1076.
15. Krop M, de Bruyn JH, Derkx FH et al. Renin and prorenin disappearance
in humans post-nephrectomy: evidence for binding? Front Biosci 2008;
13: 3931–3939.
16. Krop M, Danser AH. Circulating versus tissue renin-angiotensin system:
on the origin of (pro)renin. Curr Hypertens Rep 2008; 10: 112–118.
17. van Kesteren CA, Saris JJ, Dekkers DH et al. Cultured neonatal rat cardiac
myocytes and fibroblasts do not synthesize renin or angiotensinogen:
evidence for stretch-induced cardiomyocyte hypertrophy independent
of angiotensin II. Cardiovasc Res 1999; 43: 148–156.
18. Maru I, Ohta Y, Murata K et al. Molecular cloning and identification
of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a
renin-binding protein. J Biol Chem 1996; 271: 16294–16299.
19. Schmitz C, Gotthardt M, Hinderlich S et al. Normal blood pressure and
plasma renin activity in mice lacking the renin-binding protein, a cellular
renin inhibitor. J Biol Chem 2000; 275: 15357–15362.
20. Saris JJ, Derkx FH, De Bruin RJ et al. High-affinity prorenin binding to
cardiac man-6-P/IGF-II receptors precedes proteolytic activation to
renin. Am J Physiol Heart Circ Physiol 2001; 280: H1706–H1715.
21. Saris JJ, Derkx FH, Lamers JM et al. Cardiomyocytes bind and activate
native human prorenin : role of soluble mannose 6-phosphate
receptors. Hypertension 2001; 37: 710–715.
22. Saris JJ, van den Eijnden MM, Lamers JM et al. Prorenin-induced
myocyte proliferation: no role for intracellular angiotensin II.
Hypertension 2002; 39: 573–577.
23. van den Eijnden MM, Saris JJ, de Bruin RJ et al. Prorenin accumulation
and activation in human endothelial cells: importance of mannose
6-phosphate receptors. Arterioscler Thromb Vasc Biol 2001; 21:
911–916.
24. van Kesteren CA, Danser AH, Derkx FH et al. Mannose 6-phosphate
receptor-mediated internalization and activation of prorenin by
cardiac cells. Hypertension 1997; 30: 1389–1396.
25. Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)renin
receptor. Curr Opin Pharmacol 2008; 8: 127–132.
26. Su AI, Wiltshire T, Batalov S et al. A gene atlas of the mouse and human
protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101:
6062–6067.
27. Ichihara A, Kaneshiro Y, Takemitsu T et al. The (pro)renin receptor and
the kidney. Semin Nephrol 2007; 27: 524–528.
28. Sakoda M, Ichihara A, Kurauchi-Mito A et al. Aliskiren inhibits
intracellular angiotensin II levels Without Affecting (Pro)renin Receptor
Signals in Human Podocytes. Am J Hypertens 2010; 23: 575–580.
29. Advani A, Kelly DJ, Cox AJ et al. The (Pro)renin receptor: site-specific and
functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension
2009; 54: 261–269.
30. Nabi AH, Kageshima A, Uddin MN et al. Binding properties of rat
prorenin and renin to the recombinant rat renin/prorenin receptor
prepared by a baculovirus expression system. Int J Mol Med 2006; 18:
483–488.
31. Nguyen G, Delarue F, Berrou J et al. Specific receptor binding of renin on
human mesangial cells in culture increases plasminogen activator
inhibitor-1 antigen. Kidney Int 1996; 50: 1897–1903.
32. Batenburg WW, Krop M, Garrelds IM et al. Prorenin is the endogenous
agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin
in rat vascular smooth muscle cells overexpressing the human
(pro)renin receptor. J Hypertens 2007; 25: 2441–2453.
33. Saris JJ, t Hoen PA, Garrelds IM et al. Prorenin induces intracellular
signaling in cardiomyocytes independently of angiotensin II.
Hypertension 2006; 48: 564–571.
34. Sakoda M, Ichihara A, Kaneshiro Y et al. (Pro)renin receptor-mediated
activation of mitogen-activated protein kinases in human vascular
smooth muscle cells. Hypertens Res 2007; 30: 1139–1146.
35. Melnyk RA, Tam J, Boie Y et al. Renin and prorenin activate pathways
implicated in organ damage in human mesangial cells independent
of angiotensin II production. Am J Nephrol 2009; 30: 232–243.
36. Feldt S, Batenburg WW, Mazak I et al. Prorenin and renin-induced
extracellular signal-regulated kinase 1/2 activation in monocytes is
not blocked by aliskiren or the handle-region peptide. Hypertension
2008; 51: 682–688.
37. Kaneshiro Y, Ichihara A, Takemitsu T et al. Increased expression of
cyclooxygenase-2 in the renal cortex of human prorenin receptor
gene-transgenic rats. Kidney Int 2006; 70: 641–646.
38. Zhang J, Noble NA, Border WA et al. Receptor-dependent prorenin
activation and induction of PAI-1 expression in vascular smooth muscle
cells. Am J Physiol Endocrinol Metab 2008; 295: E810–E819.
39. Huang J, Siragy HM. Glucose promotes the production of interleukine-
1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin
receptor expression. Endocrinology 2009; 150: 5557–5565.
40. Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to
diabetic nephropathy through enhancing renal inflammation. Clin Exp
Pharmacol Physiol 2009; 37: 277–282.
41. Alcazar O, Cousins SW, Striker GE et al. (Pro)renin receptor is expressed
in human retinal pigment epithelium and participates in extracellular
matrix remodeling. Exp Eye Res 2009; 89: 638–647.
42. Satofuka S, Ichihara A, Nagai N et al. (Pro)renin receptor promotes
choroidal neovascularization by activating its signal transduction
and tissue renin-angiotensin system. Am J Pathol 2008; 173:
1911–1918.
43. Satofuka S, Ichihara A, Nagai N et al. (Pro)renin receptor-mediated signal
transduction and tissue renin-angiotensin system contribute to
diabetes-induced retinal inflammation. Diabetes 2009; 58: 1625–1633.
44. Uraoka M, Ikeda K, Nakagawa Y et al. Prorenin induces ERK activation in
endothelial cells to enhance neovascularization independently of the
renin-angiotensin system. Biochem Biophys Res Commun 2009; 390:
1202–1207.
45. Schefe JH, Menk M, Reinemund J et al. A novel signal transduction
cascade involving direct physical interaction of the renin/prorenin
receptor with the transcription factor promyelocytic zinc finger protein.
Circ Res 2006; 99: 1355–1366.
46. Schefe JH, Neumann C, Goebel M et al. Prorenin engages the (pro)renin
receptor like renin and both ligand activities are unopposed by aliskiren.
J Hypertens 2008; 26: 1787–1794.
47. Krebs C, Hamming I, Sadaghiani S et al. Antihypertensive therapy
upregulates renin and (pro)renin receptor in the clipped kidney of
Goldblatt hypertensive rats. Kidney Int 2007; 72: 725–730.
48. Burckle C, Bader M. Prorenin and its ancient receptor. Hypertension 2006;
48: 549–551.
49. Cousin C, Bracquart D, Contrepas A et al. Soluble form of the (pro)renin
receptor generated by intracellular cleavage by furin is secreted in
plasma. Hypertension 2009; 53: 1077–1082.
50. Bader M. The second life of the (pro)renin receptor. J Renin Angiotensin
Aldosterone Syst 2007; 8: 205–208.
51. Deinum J, Ronn B, Mathiesen E et al. Increase in serum prorenin
precedes onset of microalbuminuria in patients with insulin-dependent
diabetes mellitus. Diabetologia 1999; 42: 1006–1010.
52. Luetscher JA, Kraemer FB, Wilson DM et al. Increased plasma inactive
renin in diabetes mellitus. A marker of microvascular complications. N
Engl J Med 1985; 312: 1412–1417.
53. Stankovic AR, Fisher ND, Hollenberg NK. Prorenin and angiotensin-
dependent renal vasoconstriction in type 1 and type 2 diabetes. J Am
Soc Nephrol 2006; 17: 3293–3299.
54. Veniant M, Menard J, Bruneval P et al. Vascular damage without
hypertension in transgenic rats expressing prorenin exclusively in the
liver. J Clin Invest 1996; 98: 1966–1970.
55. Prescott G, Silversides DW, Reudelhuber TL. Tissue activity of circulating
prorenin. Am J Hypertens 2002; 15: 280–285.
56. Methot D, Silversides DW, Reudelhuber TL. In vivo enzymatic assay
reveals catalytic activity of the human renin precursor in tissues. Circ Res
1999; 84: 1067–1072.
57. Hsueh WA, Luetscher JA, Carlson EJ et al. Changes in active and inactive
renin throughout pregnancy. J Clin Endocrinol Metab 1982; 54:
1010–1016.
254 Kidney International (2010) 78, 246–256
rev iew G Sihn et al.: Update on the (pro)renin receptor
58. Sealey JE, Wilson M, Morganti AA et al. Changes in active and inactive
renin throughout normal pregnancy. Clin Exp Hypertens A 1982; 4:
2373–2384.
59. Skinner SL, Cran EJ, Gibson R et al. Angiotensins I and II, active and, renin
substrate, renin activity, and angiotensinase in human liquor amnii and
plasma. Am J Obstet Gynecol 1975; 121: 626–630.
60. Campbell DJ, Karam H, Menard J et al. Prorenin contributes to
angiotensin peptide formation in transgenic rats with rat prorenin
expression targeted to the liver. Hypertension 2009; 54: 1248–1253.
61. Peters B, Grisk O, Becher B et al. Dose-dependent titration of prorenin
and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-
induced glomerulosclerosis. J Hypertens 2008; 26: 102–109.
62. Peters J, Schluter T, Riegel T et al. Lack of cardiac fibrosis in a new model
of high prorenin hyperaldosteronism. Am J Physiol Heart Circ Physiol
2009; 297: H1845–H1852.
63. Mercure C, Prescott G, Lacombe MJ et al. Chronic increases in circulating
prorenin are not associated with renal or cardiac pathologies.
Hypertension 2009; 53: 1062–1069.
64. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic
rats through enhanced angiotensin AT1 receptor and NADPH oxidase
activity. Exp Physiol 2008; 93: 709–714.
65. Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin
gene expression in the kidney by paricalcitol. Kidney Int 2008; 74:
1394–1402.
66. Hirose T, Mori N, Totsune K et al. Increased expression of (pro)renin
receptor in the remnant kidneys of 5/6 nephrectomized rats. Regul Pept
2010; 159: 93–99.
67. Hirose T, Mori N, Totsune K et al. Gene expression of (pro)renin receptor
is upregulated in hearts and kidneys of rats with congestive heart
failure. Peptides 2009; 30: 2316–2322.
68. Ichihara A, Kaneshiro Y, Takemitsu T et al. Nonproteolytic activation of
prorenin contributes to development of cardiac fibrosis in genetic
hypertension. Hypertension 2006; 47: 894–900.
69. Kaschina E, Scholz H, Steckelings UM et al. Transition from
atherosclerosis to aortic aneurysm in humans coincides with an
increased expression of RAS components. Atherosclerosis 2009; 205:
396–403.
70. Hirose T, Hashimoto M, Totsune K et al. Association of (pro)renin
receptor gene polymorphism with blood pressure in Japanese men: the
Ohasama study. Am J Hypertens 2009; 22: 294–299.
71. Kaneshiro Y, Ichihara A, Sakoda M et al. Slowly progressive, angiotensin
II-independent glomerulosclerosis in human (pro)renin receptor-
transgenic rats. J Am Soc Nephrol 2007; 18: 1789–1795.
72. Ramser J, Abidi FE, Burckle CA et al. A unique exonic splice enhancer
mutation in a family with X-linked mental retardation and epilepsy
points to a novel role of the renin receptor. Hum Mol Genet 2005; 14:
1019–1027.
73. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic
nephropathy by a decoy peptide corresponding to the ‘handle’ region
for nonproteolytic activation of prorenin. J Clin Invest 2004; 114:
1128–1135.
74. Takahashi H, Ichihara A, Kaneshiro Y et al. Regression of nephropathy
developed in diabetes by (Pro)renin receptor blockade. J Am Soc
Nephrol 2007; 18: 2054–2061.
75. Ichihara A, Suzuki F, Nakagawa T et al. Prorenin receptor blockade
inhibits development of glomerulosclerosis in diabetic angiotensin II
type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950–1961.
76. de Cavanagh EM, Inserra F, Toblli J et al. Enalapril attenuates oxidative
stress in diabetic rats. Hypertension 2001; 38: 1130–1136.
77. Onozato ML, Tojo A, Goto A et al. Oxidative stress and nitric oxide
synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int
2002; 61: 186–194.
78. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in
type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–2446.
79. Satofuka S, Ichihara A, Nagai N et al. Role of nonproteolytically activated
prorenin in pathologic, but not physiologic, retinal neovascularization.
Invest Ophthalmol Vis Sci 2007; 48: 422–429.
80. Satofuka S, Ichihara A, Nagai N et al. Suppression of ocular inflammation
in endotoxin-induced uveitis by inhibiting nonproteolytic activation of
prorenin. Invest Ophthalmol Vis Sci 2006; 47: 2686–2692.
81. Susic D, Zhou X, Frohlich ED et al. Cardiovascular effects of prorenin
blockade in genetically spontaneously hypertensive rats on normal and
high-salt diet. Am J Physiol Heart Circ Physiol 2008; 295: H1117–H1121.
82. Krebs C, Weber M, Steinmetz O et al. Effect of (pro)renin receptor
inhibition by a decoy peptide on renal damage in the clipped kidney of
Goldblatt rats. Kidney Int 2008; 74: 823–824.
83. Feldt S, Maschke U, Dechend R et al. The putative (pro)renin receptor
blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008;
19: 743–748.
84. Muller DN, Klanke B, Feldt S et al. (Pro)renin receptor peptide inhibitor
‘handle-region’ peptide does not affect hypertensive nephrosclerosis in
Goldblatt rats. Hypertension 2008; 51: 676–681.
85. Nabi AH, Biswas KB, Nakagawa T et al. ‘Decoy peptide’ region
(RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin
binding to the (pro)renin receptor. Int J Mol Med 2009; 24: 83–89.
86. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of
available data from in vitro studies and experimental models in rodents.
Exp Physiol 2008; 93: 557–563.
87. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and
pathophysiology. Nat Rev Mol Cell Biol 2007; 8: 917–929.
88. Takamori S, Holt M, Stenius K et al. Molecular anatomy of a trafficking
organelle. Cell 2006; 127: 831–846.
89. Marshansky V, Futai M. The V-type H+-ATPase in vesicular trafficking:
targeting, regulation and function. Curr Opin Cell Biol 2008; 20: 415–426.
90. Hinton A, Bond S, Forgac M. V-ATPase functions in normal and disease
processes. Pflugers Arch 2009; 457: 589–598.
91. Toyomura T, Murata Y, Yamamoto A et al. From lysosomes to the plasma
membrane: localization of vacuolar-type H+ -ATPase with the a3 isoform
during osteoclast differentiation. J Biol Chem 2003; 278: 22023–22030.
92. Nomiyama H, Egami K, Wada N et al. Identification of genes differentially
expressed in osteoclast-like cells. J Interferon Cytokine Res 2005; 25:
227–231.
93. Guinea R, Carrasco L. Requirement for vacuolar proton-ATPase activity
during entry of influenza virus into cells. J Virol 1995; 69: 2306–2312.
94. Karlas A, Machuy N, Shin Y et al. Genome-wide RNAi screen identifies
human host factors crucial for influenza virus replication. Nature 2010;
463: 818–822.
95. Konig R, Stertz S, Zhou Y et al. Human host factors required for influenza
virus replication. Nature 2010; 463: 813–817.
96. Contrepas A, Walker J, Koulakoff A et al. A role of the (pro)renin receptor
in neuronal cell differentiation. Am J Physiol Regul Integr Comp Physiol
2009; 297: R250–R257.
97. Nuckels RJ, Ng A, Darland T et al. The vacuolar-ATPase complex
regulates retinoblast proliferation and survival, photoreceptor
morphogenesis, and pigmentation in the zebrafish eye. Invest
Ophthalmol Vis Sci 2009; 50: 893–905.
98. Tabata H, Kawamura N, Sun-Wada GH et al. Vacuolar-type H(+)-ATPase
with the a3 isoform is the proton pump on premature melanosomes.
Cell Tissue Res 2008; 332: 447–460.
99. Ille F, Sommer L. Wnt signaling: multiple functions in neural
development. Cell Mol Life Sci 2005; 62: 1100–1108.
100. Malaterre J, Ramsay RG, Mantamadiotis T. Wnt-Frizzled signalling and
the many paths to neural development and adult brain homeostasis.
Front Biosci 2007; 12: 492–506.
101. Dunn KJ, Brady M, Ochsenbauer-Jambor C et al. WNT1 and WNT3a
promote expansion of melanocytes through distinct modes of action.
Pigment Cell Res 2005; 18: 167–180.
102. Supek F, Supekova L, Mandiyan S et al. A novel accessory subunit for
vacuolar H(+)-ATPase from chromaffin granules. J Biol Chem 1994; 269:
24102–24106.
103. Schoonderwoert VT, Martens GJ. Targeted disruption of the mouse gene
encoding the V-ATPase accessory subunit Ac45. Mol Membr Biol 2002;
19: 67–71.
104. Huelsken J, Vogel R, Brinkmann V et al. Requirement for beta-catenin in
anterior-posterior axis formation in mice. J Cell Biol 2000; 148: 567–578.
105. Nielsen AH, Hermann KL, Mazanti I et al. Urinary excretion of inactive
renin during blockade of the renal tubular protein reabsorption with
lysine. J Hypertens 1989; 7: 77–82.
106. Yukimura T, Miura K, Matsushima Y et al. Urinary excretion of renin and
its biochemical properties in dogs. Hypertension 1984; 6: 837–842.
107. Prieto-Carrasquero MC, Botros FT, Kobori H et al. Collecting duct renin: a
major player in angiotensin II-dependent hypertension. J Am Soc
Hypertens 2009; 3: 96–104.
108. Kang JJ, Toma I, Sipos A et al. The collecting duct is the major source of
prorenin in diabetes. Hypertension 2008; 51: 1597–1604.
109. Schmidt-Ott KM, Barasch J. WNT/beta-catenin signaling in nephron
progenitors and their epithelial progeny. Kidney Int 2008; 74:
1004–1008.
110. Pulkkinen K, Murugan S, Vainio S. Wnt signaling in kidney development
and disease. Organogenesis 2008; 4: 55–59.
111. He W, Dai C, Li Y et al. Wnt/beta-catenin signaling promotes renal
interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765–776.
Kidney International (2010) 78, 246–256 255
G Sihn et al.: Update on the (pro)renin receptor r ev iew
112. Dai C, Stolz DB, Kiss LP et al. Wnt/beta-catenin signaling promotes
podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20:
1997–2008.
113. Lin CL, Wang JY, Ko JY et al. Dickkopf-1 promotes hyperglycemia-
induced accumulation of mesangial matrix and renal dysfunction. J Am
Soc Nephrol 2010; 21: 124–135.
114. Lancaster MA, Louie CM, Silhavy JL et al. Impaired Wnt-beta-catenin
signaling disrupts adult renal homeostasis and leads to cystic kidney
ciliopathy. Nat Med 2009; 15: 1046–1054.
115. Scita G, Di Fiore PP. The endocytic matrix. Nature 2010; 463: 464–473.
116. Kovacs JJ, Hara MR, Davenport CL et al. Arrestin development: emerging
roles for beta-arrestins in developmental signaling pathways. Dev Cell
2009; 17: 443–458.
117. Horng JL, Lin LY, Huang CJ et al. Knockdown of V-ATPase subunit A
(atp6v1a) impairs acid secretion and ion balance in zebrafish (Danio
rerio). Am J Physiol Regul Integr Comp Physiol 2007; 292: R2068–R2076.
118. Ferea TL, Bowman BJ. The vacuolar ATPase of Neurospora crassa is
indispensable: inactivation of the vma-1 gene by repeat-induced point
mutation. Genetics 1996; 143: 147–154.
119. Klionsky DJ, Nelson H, Nelson N et al. Mutations in the yeast vacuolar
ATPase result in the mislocalization of vacuolar proteins. J Exp Biol 1992;
172: 83–92.
120. Nelson H, Nelson N. Disruption of genes encoding subunits of yeast
vacuolar H(+)-ATPase causes conditional lethality. Proc Natl Acad Sci USA
1990; 87: 3503–3507.
121. Davies SA, Goodwin SF, Kelly DC et al. Analysis and inactivation of
vha55, the gene encoding the vacuolar ATPase B-subunit in Drosophila
melanogaster reveals a larval lethal phenotype. J Biol Chem 1996; 271:
30677–30684.
122. Karet FE, Finberg KE, Nelson RD et al. Mutations in the gene encoding B1
subunit of H+-ATPase cause renal tubular acidosis with sensorineural
deafness. Nat Genet 1999; 21: 84–90.
123. Stover EH, Borthwick KJ, Bavalia C et al. Novel ATP6V1B1 and ATP6V0A4
mutations in autosomal recessive distal renal tubular acidosis with new
evidence for hearing loss. J Med Genet 2002; 39: 796–803.
124. Smith AN, Skaug J, Choate KA et al. Mutations in ATP6N1B, encoding a
new kidney vacuolar proton pump 116-kD subunit, cause recessive
distal renal tubular acidosis with preserved hearing. Nat Genet 2000; 26:
71–75.
125. Finberg KE, Wagner CA, Bailey MA et al. The B1-subunit of the H(+)
ATPase is required for maximal urinary acidification. Proc Natl Acad Sci
USA 2005; 102: 13616–13621.
126. Yang Q, Li G, Singh SK et al. Vacuolar H+ -ATPase B1 subunit mutations
that cause inherited distal renal tubular acidosis affect proton pump
assembly and trafficking in inner medullary collecting duct cells. J Am
Soc Nephrol 2006; 17: 1858–1866.
127. Oka T, Futai M. Requirement of V-ATPase for ovulation and
embryogenesis in Caenorhabditis elegans. J Biol Chem 2000; 275:
29556–29561.
128. Feng S, Deng L, Chen W et al. Atp6v1c1 is an essential component of the
osteoclast proton pump and in F-actin ring formation in osteoclasts.
Biochem J 2009; 417: 195–203.
129. Lu M, Vergara S, Zhang L et al. The amino-terminal domain of the E
subunit of vacuolar H(+)-ATPase (V-ATPase) interacts with the H subunit
and is required for V-ATPase function. J Biol Chem 2002; 277:
38409–38415.
130. Liegeois S, Benedetto A, Garnier JM et al. The V0-ATPase mediates apical
secretion of exosomes containing Hedgehog-related proteins in
Caenorhabditis elegans. J Cell Biol 2006; 173: 949–961.
131. Peri F, Nusslein-Volhard C. Live imaging of neuronal degradation by
microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo.
Cell 2008; 133: 916–927.
132. Hiesinger PR, Fayyazuddin A, Mehta SQ et al. The v-ATPase V0 subunit
a1 is required for a late step in synaptic vesicle exocytosis in Drosophila.
Cell 2005; 121: 607–620.
133. Kornak U, Reynders E, Dimopoulou A et al. Impaired glycosylation and
cutis laxa caused by mutations in the vesicular H+-ATPase subunit
ATP6V0A2. Nat Genet 2008; 40: 32–34.
134. Sun-Wada GH, Toyomura T, Murata Y et al. The a3 isoform of V-ATPase
regulates insulin secretion from pancreatic beta-cells. J Cell Sci 2006;
119: 4531–4540.
135. Li YP, Chen W, Liang Y et al. Atp6i-deficient mice exhibit severe
osteopetrosis due to loss of osteoclast-mediated extracellular
acidification. Nat Genet 1999; 23: 447–451.
136. Frattini A, Orchard PJ, Sobacchi C et al. Defects in TCIRG1 subunit of the
vacuolar proton pump are responsible for a subset of human autosomal
recessive osteopetrosis. Nat Genet 2000; 25: 343–346.
137. Scimeca JC, Quincey D, Parrinello H et al. Novel mutations in the TCIRG1
gene encoding the a3 subunit of the vacuolar proton pump in patients
affected by infantile malignant osteopetrosis. Hum Mutat 2003; 21:
151–157.
138. Susani L, Pangrazio A, Sobacchi C et al. TCIRG1-dependent recessive
osteopetrosis: mutation analysis, functional identification of the
splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat 2004;
24: 225–235.
139. Scimeca JC, Franchi A, Trojani C et al. The gene encoding the mouse
homologue of the human osteoclast-specific 116-kDa V-ATPase subunit
bears a deletion in osteosclerotic (oc/oc) mutants. Bone 2000; 26:
207–213.
140. Hu Y, Nyman J, Muhonen P et al. Inhibition of the osteoclast V-ATPase
by small interfering RNAs. FEBS Lett 2005; 579: 4937–4942.
141. Laitala-Leinonen T, Lowik C, Papapoulos S et al. Inhibition of
intravacuolar acidification by antisense RNA decreases osteoclast
differentiation and bone resorption in vitro. J Cell Sci 1999; 112(Part 21):
3657–3666.
142. Inoue H, Noumi T, Nagata M et al. Targeted disruption of the gene
encoding the proteolipid subunit of mouse vacuolar H(+)-ATPase leads
to early embryonic lethality. Biochim Biophys Acta 1999; 1413: 130–138.
143. Sun-Wada G, Murata Y, Yamamoto A et al. Acidic endomembrane
organelles are required for mouse postimplantation development. Dev
Biol 2000; 228: 315–325.
144. Lu X, Qin W, Li J et al. The growth and metastasis of human
hepatocellular carcinoma xenografts are inhibited by small interfering
RNA targeting to the subunit ATP6L of proton pump. Cancer Res 2005;
65: 6843–6849.
145. Miura GI, Froelick GJ, Marsh DJ et al. The d subunit of the vacuolar
ATPase (Atp6d) is essential for embryonic development. Transgenic Res
2003; 12: 131–133.
146. Lee SH, Rho J, Jeong D et al. v-ATPase V0 subunit d2-deficient mice
exhibit impaired osteoclast fusion and increased bone formation. Nat
Med 2006; 12: 1403–1409.
147. Wu H, Xu G, Li YP. Atp6v0d2 is an essential component of the
osteoclast-specific proton pump that mediates extracellular acidification
in bone resorption. J Bone Miner Res 2009; 24: 871–885.
148. Feng H, Cheng T, Pavlos NJ et al. Cytoplasmic terminus of vacuolar type
proton pump accessory subunit Ac45 is required for proper interaction
with V(0) domain subunits and efficient osteoclastic bone resorption.
J Biol Chem 2008; 283: 13194–13204.
256 Kidney International (2010) 78, 246–256
rev iew G Sihn et al.: Update on the (pro)renin receptor
